Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRosenstock, Julio
dc.contributor.authorGuerci, Bruno
dc.contributor.authorHanefeld, Markolf
dc.contributor.authorGentile, Sandro
dc.contributor.authorAronson, Ronnie
dc.contributor.authorTinahones, Francisco J
dc.contributor.authorRoy-Duval, Christine
dc.contributor.authorSouhami, Elisabeth
dc.contributor.authorWardecki, Marek
dc.contributor.authorYe, Jenny
dc.contributor.authorPerfetti, Riccardo
dc.contributor.authorHeller, Simon
dc.contributor.authorGetGoal Duo-2 Trial Investigators
dc.description.abstractTo provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1-3 oral antidiabetic agents (OADs). Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained ≥7 to ≤9% (≥53 to ≤75 mmol/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization. Coprimary end points at 26 weeks were 1) noninferiority (95% CI upper bound Baseline characteristics were similar between arms (n = 298, diabetes and basal insulin duration of 12.2 and 3.2 years, respectively; BMI 32.2 kg/m(2)). HbA1c improved from 8.5% to 7.9% (69 to 63 mmol/mol) with glargine optimization and further to 7.2%, 7.2%, and 7.0% (55, 55, and 53 mmol/mol) with lixisenatide and glulisine once daily and thrice daily, respectively; all coprimary end points were met. Symptomatic hypoglycemia and body weight were lower in lixisenatide versus glulisine patients. More gastrointestinal events occurred with lixisenatide. Short-acting glucagon-like peptide-1 receptor agonists as add-on to basal insulin may become a preferred treatment intensification option, attaining meaningful glycemic targets with fewer hypoglycemic events without weight gain versus basal-plus or basal-bolus in uncontrolled basal insulin-treated type 2 diabetes.
dc.subject.meshBlood Glucose
dc.subject.meshBody Mass Index
dc.subject.meshBody Weight
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshDrug Therapy, Combination
dc.subject.meshEndpoint Determination
dc.subject.meshGlucagon-Like Peptide-1 Receptor
dc.subject.meshGlycated Hemoglobin
dc.subject.meshHypoglycemic Agents
dc.subject.meshInsulin Glargine
dc.subject.meshMiddle Aged
dc.subject.meshPostprandial Period
dc.titlePrandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
dc.typeresearch article
dc.journal.titleDiabetes care
dc.journal.titleabbreviationDiabetes Care
dc.organizationHospital Universitario Virgen de la Victoria
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.